WKRU investigators contributed to the DAPA-CKD clinical trial
09/12/2020
Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, was not known. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial (NCT03036150) set to assess the effect of the SGLT2 inhibitor dapagliflozin on renal and cardiovascular events in a broad range of patients with CKD with and without diabetes.
Found out more about the scientific results here:
Dapagliflozin in Patients with Chronic Kidney Disease. https://pubmed.ncbi.nlm.nih.gov/32970396/
Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease. https://pubmed.ncbi.nlm.nih.gov/33186054/
Previous publication:
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. https://pubmed.ncbi.nlm.nih.gov/32030417/
